AstraZeneca Buys Into In Vivo Cell Therapy Potential With EsoBiotec
The acquisition is worth up to $1bn and adds to AstraZeneca’s broad array of cell therapy technologies.
The acquisition is worth up to $1bn and adds to AstraZeneca’s broad array of cell therapy technologies.